Head-to-head evidence
Paliperidone palmitate (Invega Hafyera) vs Risperidone (QUAR)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline
Paliperidone palmitate (Invega Hafyera)
Marketed by Johnson & Johnson
NCT03345342 · Phase 3 · completed
After an open-label stabilization phase, 702 participants were randomized to six-month or three-month paliperidone palmitate and treated double-blind with matching injections, including placebo injections to preserve masking. The primary endpoint was the clinical outcome of time to relapse, but the registry reports that the median was not estimable in either group and does not provide a p-value or confidence interval, so the result cannot be classified as clearly met or missed.
Risperidone (QUAR)
Developed by Laboratorios Farmacéuticos Rovi, S.A.
NCT06276361 · Phase 1 · completed
A sequential, open-label pharmacokinetic study of quarterly-injection risperidone in 58 participants, with pharmacokinetic parameters as the primary measures. The design is uncontrolled for treatment effect and no results have been posted to the registry, so this is weak evidence.
Next expected readout: December 2027 · NCT07047651 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Paliperidone palmitate (Invega Hafyera)'s landscape · Risperidone (QUAR)'s landscape